NASDAQ:CYTR

LadRx (CYTR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CYTR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.09
▼
$0.10
52-Week Range: N/A

Volume: 4,000 shs
Average Volume: 99,706 shs
Market Capitalization: $4.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get LadRx alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About LadRx Stock (NASDAQ:CYTR)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CYTR Stock News Headlines

May 17, 2023 | investing.com

LadRx (LADX) Earnings Dates & Reports

March 29, 2023 | stockhouse.com

LadRx Highlights Patent Issued for Its LADR Technology

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 5, 2022 | finance.yahoo.com

LadRx Corporation Announces OTCQB Ticker Change to LADX

September 23, 2022 | finance.yahoo.com

CytRx Corporation Relaunches as LadRx Corporation

September 8, 2022 | seekingalpha.com

European patent office awards CytRx patent for LADR platform

September 7, 2022 | finance.yahoo.com

European Patent Office Awards CytRx Key Patent

August 3, 2022 | marketwatch.com

Temperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

August 2, 2022 | thestreet.com

Whiplash: S&P Veers to All-Time High Before Crashing

May 19, 2022 | finance.yahoo.com

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

May 18, 2022 | marketwatch.com

Kinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of value

See More Headlines

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Manufacturing
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:CYTR
CUSIP: N/A
CIK: N/A
Web: www.cytrx.com
Phone: (310) 826-5648
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 45,037,000
Free Float: N/A
Market Cap: $4.14 million
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Stephen Snowdy
Chief Executive Officer
John Y. Caloz
Chief Financial Officer, Treasurer & Senior VP
Felix Kratz
Vice President-Drug Discovery
Cristina Newman
Secretary

Key Competitors

View All Competitors

This page (NASDAQ:CYTR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LadRx (CYTR) Stock Price, News & Analysis

About LadRx Stock (NASDAQ:CYTR)

CYTR Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info